Abstract 3755: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214
Saul Kivimäe(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States)), Werner Rubas(University of California, San Francisco), Marlene Hennessy(Nektar Therapeutics (United States)), Haiying Cai(Zhejiang University of Science and Technology), Neel K. Anand(ETH Zurich), Janet Cetz(Nektar Therapeutics (United States)), Steve Doberstein(Nektar Therapeutics (United States)), Zhongxu Ren(Nektar Therapeutics (United States)), Yolanda Kirksey(Princeton University), Christie Fanton(Nektar Therapeutics (United States)), Wen Zhang(Xidian University), Bo‐Liang Deng(Nektar Therapeutics (United States)), Rhoneil Pena(Nektar Therapeutics (United States)), Phi Quatch(Nektar Therapeutics (United States)), John L. Langowski(Novartis (Switzerland)), Wildaliz Nieves(Nektar Therapeutics (United States))
Cited by 19
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
A Simple, Mild, Catalytic, Enantioselective Addition of Terminal Acetylenes to Aldehydes
|Journal of the American Chemical Society|2001|470
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403
Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels
|Journal of Neuroscience|2008|351